{{!--
  Investigator's Brochure - Generic Product
  Section 7: Efficacy and Clinical Outcomes
  
  Template for ICH E6 (R2) compliant IB Section 7
  
  Data Sources:
  - clinical_summary (efficacy data, outcomes)
  - trials (clinical trial results)
  - literature (efficacy studies)
  - label (indications, clinical studies section)
  
  Variables:
  - compound_name: string
  - generic_name: string
  - rld_brand_name: string
  - clinical_summary: ClinicalSummary
  - trials: Trial[]
  - literature: Literature[]
  - label: Label
--}}

# 7. EFFICACY AND CLINICAL OUTCOMES

## 7.1 Overview

This section summarizes the efficacy and clinical outcomes of {{compound_name}} ({{generic_name}}), based on data from the Reference Listed Drug (RLD) {{rld_brand_name}} and supporting scientific literature.

{{#if clinical_summary}}
{{compound_name}} has been evaluated in {{#if clinical_summary.total_studies}}{{clinical_summary.total_studies}}{{else}}[number]{{/if}} clinical studies involving {{#if clinical_summary.total_subjects}}{{clinical_summary.total_subjects}}{{else}}[number]{{/if}} subjects across {{#if clinical_summary.phases_studied}}{{join clinical_summary.phases_studied ", "}}{{else}}[phases]{{/if}}.
{{else}}
{{compound_name}} has been extensively studied in clinical trials to establish its efficacy for the approved indication(s).
{{/if}}

---

## 7.2 Approved Indications

{{#if label.sections.indications_and_usage}}
{{label.sections.indications_and_usage}}
{{else}}
{{#if clinical_summary.indications_studied}}
{{compound_name}} is indicated for:
{{#each clinical_summary.indications_studied}}
- {{this}}
{{/each}}
{{else}}
{{compound_name}} is indicated for [indication].
{{/if}}
{{/if}}

---

## 7.3 Clinical Development Program

### 7.3.1 Study Overview

{{#if clinical_summary}}
The clinical development program for {{rld_brand_name}} (reference for {{compound_name}}) included:

**Study Phases:**
{{#if clinical_summary.phases_studied}}
{{#each clinical_summary.phases_studied}}
- {{this}}
{{/each}}
{{else}}
- Phase 1: Pharmacokinetics and safety
- Phase 2: Dose-finding and preliminary efficacy
- Phase 3: Pivotal efficacy and safety trials
- Phase 4: Post-marketing surveillance
{{/if}}

**Total Subjects Enrolled:** {{#if clinical_summary.total_subjects}}{{clinical_summary.total_subjects}}{{else}}[number]{{/if}}

**Total Studies:** {{#if clinical_summary.total_studies}}{{clinical_summary.total_studies}}{{else}}[number]{{/if}}

**Study Populations:**
{{#if clinical_summary.populations_studied}}
{{#each clinical_summary.populations_studied}}
- {{this}}
{{/each}}
{{else}}
- [Population 1]
- [Population 2]
{{/if}}
{{else}}
The clinical development program for {{rld_brand_name}} included multiple phases of clinical trials to establish efficacy and safety.
{{/if}}

### 7.3.2 Key Efficacy Endpoints

{{#if clinical_summary.efficacy_data}}
**Primary Endpoints:**
{{#if clinical_summary.efficacy_data.primary_endpoints}}
{{#each clinical_summary.efficacy_data.primary_endpoints}}
- {{this.endpoint}}: {{this.description}}
{{/each}}
{{else}}
- [Primary endpoint 1]
- [Primary endpoint 2]
{{/if}}

**Secondary Endpoints:**
{{#if clinical_summary.efficacy_data.secondary_endpoints}}
{{#each clinical_summary.efficacy_data.secondary_endpoints}}
- {{this.endpoint}}: {{this.description}}
{{/each}}
{{else}}
- [Secondary endpoint 1]
- [Secondary endpoint 2]
{{/if}}
{{else}}
**Primary Endpoints:**
- [Primary endpoint]

**Secondary Endpoints:**
- [Secondary endpoint 1]
- [Secondary endpoint 2]
{{/if}}

---

## 7.4 Pivotal Clinical Trials

{{#if trials}}
{{#each trials}}
### 7.4.{{add @index 1}} {{this.title}} ({{this.registry_id}})

**Study Design:**
- **Type:** {{#if this.trial_design.study_type}}{{this.trial_design.study_type}}{{else}}[type]{{/if}}
- **Phase:** {{#if this.phase}}{{this.phase}}{{else}}[phase]{{/if}}
- **Allocation:** {{#if this.trial_design.allocation}}{{this.trial_design.allocation}}{{else}}[allocation]{{/if}}
- **Masking:** {{#if this.trial_design.masking}}{{this.trial_design.masking}}{{else}}[masking]{{/if}}
- **Primary Purpose:** {{#if this.trial_design.primary_purpose}}{{this.trial_design.primary_purpose}}{{else}}[purpose]{{/if}}

**Study Population:**
- **Indication:** {{#if this.indication}}{{this.indication}}{{else}}[indication]{{/if}}
- **Enrollment:** {{#if this.trial_design.enrollment_n}}N={{this.trial_design.enrollment_n}}{{else}}N=[number]{{/if}} subjects
{{#if this.inclusion_criteria}}
- **Key Inclusion Criteria:** {{this.inclusion_criteria}}
{{/if}}

**Treatment Arms:**
{{#if this.arms}}
{{#each this.arms}}
- **{{this.arm_name}}** ({{this.arm_type}}){{#if this.n}}: N={{this.n}}{{/if}}
  {{#if this.description}}{{this.description}}{{/if}}
{{/each}}
{{else}}
- [Arm 1]
- [Arm 2]
{{/if}}

**Outcomes:**
{{#if this.outcomes}}
{{#each this.outcomes}}
**{{capitalize this.outcome_type}} Outcome:** {{this.measure}}
{{#if this.time_frame}}- Time Frame: {{this.time_frame}}{{/if}}
{{#if this.result}}
- Result: {{this.result}}{{#if this.unit}} {{this.unit}}{{/if}}
{{#if this.n}}- N: {{this.n}}{{/if}}
{{#if this.mean}}- Mean: {{decimal this.mean 2}}{{#if this.sd}} (SD: {{decimal this.sd 2}}){{/if}}{{/if}}
{{#if this.p_value}}- P-value: {{this.p_value}}{{/if}}
{{/if}}

{{/each}}
{{else}}
- [Outcome 1]
- [Outcome 2]
{{/if}}

**Conclusion:** {{#if this.conclusion}}{{this.conclusion}}{{else}}[Summarize key findings and clinical significance]{{/if}}

**Source:** {{#if this.source_url}}{{this.source_url}}{{else}}ClinicalTrials.gov{{/if}}

---

{{/each}}
{{else}}
### 7.4.1 Pivotal Trial 1

**Study Design:** [Describe study design]

**Study Population:** [Describe population]

**Treatment Arms:** [List arms]

**Outcomes:** [Describe outcomes]

**Conclusion:** [Summarize findings]

---

### 7.4.2 Pivotal Trial 2

**Study Design:** [Describe study design]

**Study Population:** [Describe population]

**Treatment Arms:** [List arms]

**Outcomes:** [Describe outcomes]

**Conclusion:** [Summarize findings]

---

{{/if}}

## 7.5 Efficacy Results Summary

### 7.5.1 Primary Efficacy Outcomes

{{#if clinical_summary.efficacy_data}}
{{#if clinical_summary.efficacy_data.primary_results}}
{{#each clinical_summary.efficacy_data.primary_results}}
**{{this.endpoint}}**
- **Result:** {{this.result}}{{#if this.unit}} {{this.unit}}{{/if}}
{{#if this.comparator}}- **Comparator:** {{this.comparator}}{{/if}}
{{#if this.difference}}- **Difference:** {{this.difference}}{{#if this.ci_95}} (95% CI: {{this.ci_95}}){{/if}}{{/if}}
{{#if this.p_value}}- **P-value:** {{this.p_value}}{{/if}}
- **Clinical Significance:** {{#if this.clinical_significance}}{{this.clinical_significance}}{{else}}[Describe clinical significance]{{/if}}

{{/each}}
{{else}}
[Summarize primary efficacy outcomes from pivotal trials]
{{/if}}
{{else}}
[Summarize primary efficacy outcomes from pivotal trials]
{{/if}}

### 7.5.2 Secondary Efficacy Outcomes

{{#if clinical_summary.efficacy_data}}
{{#if clinical_summary.efficacy_data.secondary_results}}
{{#each clinical_summary.efficacy_data.secondary_results}}
**{{this.endpoint}}**
- **Result:** {{this.result}}{{#if this.unit}} {{this.unit}}{{/if}}
{{#if this.p_value}}- **P-value:** {{this.p_value}}{{/if}}

{{/each}}
{{else}}
[Summarize secondary efficacy outcomes from pivotal trials]
{{/if}}
{{else}}
[Summarize secondary efficacy outcomes from pivotal trials]
{{/if}}

### 7.5.3 Subgroup Analyses

{{#if clinical_summary.efficacy_data.subgroup_analyses}}
{{#each clinical_summary.efficacy_data.subgroup_analyses}}
**{{this.subgroup}}**
- {{this.finding}}
{{#if this.p_value}}- P-value: {{this.p_value}}{{/if}}

{{/each}}
{{else}}
[Describe efficacy in key subgroups: age, gender, race, disease severity, etc.]
{{/if}}

---

## 7.6 Dose-Response Relationship

{{#if clinical_summary.efficacy_data.dose_response}}
{{clinical_summary.efficacy_data.dose_response}}
{{else}}
[Describe dose-response relationship, optimal dose, dose-ranging studies]

**Recommended Dose:** [dose and frequency]

**Dose Adjustments:** [Describe dose adjustments for special populations]
{{/if}}

---

## 7.7 Duration of Effect

{{#if clinical_summary.efficacy_data.duration_of_effect}}
{{clinical_summary.efficacy_data.duration_of_effect}}
{{else}}
[Describe duration of therapeutic effect, time to onset, maintenance of effect]
{{/if}}

---

## 7.8 Comparative Efficacy

{{#if clinical_summary.efficacy_data.comparative_efficacy}}
### 7.8.1 Head-to-Head Comparisons

{{#each clinical_summary.efficacy_data.comparative_efficacy}}
**vs. {{this.comparator}}**
- **Study:** {{this.study_id}}
- **Outcome:** {{this.outcome}}
- **Result:** {{this.result}}
{{#if this.superiority}}- **Superiority:** {{this.superiority}}{{/if}}
{{#if this.non_inferiority}}- **Non-Inferiority:** {{this.non_inferiority}}{{/if}}

{{/each}}
{{else}}
[Describe comparative efficacy vs. placebo, active comparators, or standard of care]
{{/if}}

---

## 7.9 Long-Term Efficacy

{{#if clinical_summary.efficacy_data.long_term_efficacy}}
{{clinical_summary.efficacy_data.long_term_efficacy}}
{{else}}
[Describe long-term efficacy data from extension studies, real-world evidence]
{{/if}}

---

## 7.10 Special Populations

### 7.10.1 Geriatric Patients

{{#if clinical_summary.special_populations.geriatric_efficacy}}
{{clinical_summary.special_populations.geriatric_efficacy}}
{{else}}
[Describe efficacy in elderly patients]
{{/if}}

### 7.10.2 Pediatric Patients

{{#if clinical_summary.special_populations.pediatric_efficacy}}
{{clinical_summary.special_populations.pediatric_efficacy}}
{{else}}
[Describe efficacy in pediatric patients, if applicable]
{{/if}}

### 7.10.3 Renal Impairment

{{#if clinical_summary.special_populations.renal_impairment_efficacy}}
{{clinical_summary.special_populations.renal_impairment_efficacy}}
{{else}}
[Describe efficacy in patients with renal impairment]
{{/if}}

### 7.10.4 Hepatic Impairment

{{#if clinical_summary.special_populations.hepatic_impairment_efficacy}}
{{clinical_summary.special_populations.hepatic_impairment_efficacy}}
{{else}}
[Describe efficacy in patients with hepatic impairment]
{{/if}}

---

## 7.11 Supporting Literature

{{#if literature}}
The efficacy of {{compound_name}} is supported by {{length literature}} publications in peer-reviewed journals.

### 7.11.1 Key Studies

{{#each literature}}
{{#if lte @index 4}}
**{{this.title}}**  
{{#each this.authors}}{{this}}{{#unless @last}}, {{/unless}}{{/each}}  
*{{this.journal}}*{{#if this.publication_date}} ({{this.publication_date}}){{/if}}

{{#if this.abstract}}
{{this.abstract}}
{{/if}}

PMID: {{this.pmid}}  
{{#if this.source_url}}Source: {{this.source_url}}{{/if}}

---

{{/if}}
{{/each}}

### 7.11.2 Additional References

{{#each literature}}
{{#if gte @index 5}}
{{add @index 1}}. {{#each this.authors}}{{this}}{{#unless @last}}, {{/unless}}{{/each}}. {{this.title}}. {{this.journal}}{{#if this.publication_date}}. {{this.publication_date}}{{/if}}{{#if this.volume}};{{this.volume}}{{/if}}{{#if this.issue}}({{this.issue}}){{/if}}{{#if this.pages}}:{{this.pages}}{{/if}}. PMID: {{this.pmid}}.

{{/if}}
{{/each}}
{{else}}
[List key efficacy studies from literature]

1. [Reference 1]
2. [Reference 2]
3. [Reference 3]
{{/if}}

---

## 7.12 Clinical Implications

### 7.12.1 Therapeutic Benefit

{{compound_name}} has demonstrated significant therapeutic benefit in the treatment of {{#if clinical_summary.primary_indication}}{{clinical_summary.primary_indication}}{{else}}[indication]{{/if}}.

**Key Benefits:**
{{#if clinical_summary.efficacy_data.key_benefits}}
{{#each clinical_summary.efficacy_data.key_benefits}}
- {{this}}
{{/each}}
{{else}}
- [Benefit 1]
- [Benefit 2]
- [Benefit 3]
{{/if}}

### 7.12.2 Clinical Relevance

{{#if clinical_summary.efficacy_data.clinical_relevance}}
{{clinical_summary.efficacy_data.clinical_relevance}}
{{else}}
[Describe clinical relevance of efficacy findings, impact on patient outcomes, quality of life]
{{/if}}

### 7.12.3 Place in Therapy

{{#if clinical_summary.efficacy_data.place_in_therapy}}
{{clinical_summary.efficacy_data.place_in_therapy}}
{{else}}
[Describe the role of {{compound_name}} in the treatment algorithm, first-line vs. second-line, combination therapy]
{{/if}}

---

## 7.13 Summary

{{compound_name}} has demonstrated efficacy for the treatment of {{#if clinical_summary.primary_indication}}{{clinical_summary.primary_indication}}{{else}}[indication]{{/if}} in well-controlled clinical trials.

**Key Efficacy Findings:**
- {{#if clinical_summary.total_studies}}{{clinical_summary.total_studies}}{{else}}[Number]{{/if}} clinical studies involving {{#if clinical_summary.total_subjects}}{{clinical_summary.total_subjects}}{{else}}[number]{{/if}} subjects
- Demonstrated efficacy across {{#if clinical_summary.phases_studied}}{{join clinical_summary.phases_studied ", "}}{{else}}multiple phases{{/if}}
- Consistent efficacy in diverse patient populations
- Favorable benefit-risk profile

As a generic formulation, {{compound_name}} is bioequivalent to {{rld_brand_name}} and is expected to provide equivalent therapeutic efficacy.

---

## 7.14 Data Sources

This section was compiled from the following sources:

{{#if label}}
- **FDA Label:** {{label.source}} ({{label.effective_date}})
{{/if}}
{{#if clinical_summary}}
- **Clinical Summary:** {{clinical_summary.source}} (Retrieved: {{date clinical_summary.retrieved_at "YYYY-MM-DD"}})
{{/if}}
{{#if trials}}
- **Clinical Trials:** {{length trials}} trials from ClinicalTrials.gov
{{/if}}
{{#if literature}}
- **Literature:** {{length literature}} articles from PubMed
{{/if}}

**Confidence Level:** {{#if clinical_summary.confidence}}{{capitalize clinical_summary.confidence}}{{else}}High{{/if}}

---

*This section complies with ICH E6 (R2) guidelines for Investigator's Brochure content.*
